Meag Munich Ergo’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-518
| Closed | -$77.8K | – | 196 |
|
|
2024
Q4 | $77.8K | Hold |
518
| – | – | ﹤0.01% | 199 |
|
|
2024
Q3 | $100K | Buy |
+518
| New | +$108K | ﹤0.01% | 192 |
|
|
2024
Q1 | – | Sell |
-395
| Closed | -$102K | – | 181 |
|
|
2023
Q4 | $102K | Sell |
395
-1,280
| -76% | -$314K | ﹤0.01% | 157 |
|
|
2023
Q3 | $430K | Buy |
+1,675
| New | +$448K | 0.02% | 133 |
|
|
2023
Q1 | – | Sell |
-400
| Closed | -$111K | – | 184 |
|
|
2022
Q4 | $111K | Hold |
400
| – | – | 0.01% | 201 |
|
|
2022
Q3 | $107K | Sell |
400
-1,600
| -80% | -$340K | 0.01% | 197 |
|
|
2022
Q2 | $408K | Hold |
2,000
| – | – | 0.02% | 184 |
|
|
2022
Q1 | $426K | Sell |
2,000
-23,459
| -92% | -$5.1M | 0.03% | 176 |
|
|
2021
Q4 | $6.13M | Buy |
25,459
+2,212
| +10% | +$569K | 0.44% | 57 |
|
|
2021
Q3 | $6.58M | Buy |
23,247
+18,641
| +405% | +$6.11M | 1.14% | 24 |
|
|
2021
Q2 | $1.59M | Sell |
4,606
-336
| -7% | -$102K | 0.15% | 141 |
|
|
2021
Q1 | $1.38M | Buy |
4,942
+1,410
| +40% | +$380K | 0.14% | 148 |
|
|
2020
Q4 | $860K | Sell |
3,532
-1,568
| -31% | -$405K | 0.2% | 131 |
|
|
2020
Q3 | $1.45M | Sell |
5,100
-542
| -10% | -$151K | 0.27% | 95 |
|
|
2020
Q2 | $1.51M | Buy |
5,642
+1,802
| +47% | +$542K | 0.28% | 94 |
|
|
2020
Q1 | $1.22M | Sell |
3,840
-2,102
| -35% | -$638K | 0.29% | 86 |
|
|
2019
Q4 | $1.76M | Sell |
5,942
-10,066
| -63% | -$2.79M | 0.19% | 128 |
|
|
2019
Q3 | $3.67M | Buy |
16,008
+6,126
| +62% | +$1.43M | 0.19% | 119 |
|
|
2019
Q2 | $2.37M | Buy |
9,882
+594
| +6% | +$137K | 0.19% | 121 |
|
|
2019
Q1 | $2.16M | Buy |
9,288
+4,933
| +113% | +$1.55M | 0.18% | 130 |
|
|
2018
Q4 | $1.29M | Buy |
4,355
+640
| +17% | +$204K | 0.16% | 169 |
|
|
2018
Q3 | $1.31M | Buy |
3,715
+2,715
| +272% | +$935K | 0.08% | 271 |
|
|
2018
Q2 | $291K | Sell |
1,000
-11,093
| -92% | -$3.12M | 0.02% | 346 |
|
|
2018
Q1 | $3.27M | Sell |
12,093
-833
| -6% | -$259K | 0.13% | 215 |
|
|
2017
Q4 | $4.17M | Buy |
12,926
+10,126
| +362% | +$3.25M | 0.16% | 169 |
|
|
2017
Q3 | $871K | Hold |
2,800
| – | – | 0.04% | 246 |
|
|
2017
Q2 | $760K | Hold |
2,800
| – | – | 0.03% | 263 |
|
|
2017
Q1 | $751K | Sell |
2,800
-10,288
| -79% | -$2.91M | 0.03% | 299 |
|
|
2016
Q4 | $3.78M | Buy |
13,088
+10,288
| +367% | +$3.05M | 0.18% | 148 |
|
|
2016
Q3 | $857K | Hold |
2,800
| – | – | 0.04% | 210 |
|
|
2016
Q2 | $674K | Sell |
2,800
-26,275
| -90% | -$6.92M | 0.06% | 133 |
|
|
2016
Q1 | $7.58M | Sell |
29,075
-18,600
| -39% | -$4.91M | 0.39% | 89 |
|
|
2015
Q4 | $14.7M | Buy |
47,675
+45,175
| +1,807% | +$13M | 0.74% | 41 |
|
|
2015
Q3 | $722K | Buy |
2,500
+1,000
| +67% | +$330K | 0.04% | 186 |
|
|
2015
Q2 | $603K | Buy |
1,500
+400
| +36% | +$161K | 0.03% | 173 |
|
|
2015
Q1 | $472K | Hold |
1,100
| – | – | 0.02% | 176 |
|
|
2014
Q4 | $376K | Hold |
1,100
| – | – | 0.02% | 193 |
|
|
2014
Q3 | $362K | Buy |
1,100
+300
| +38% | +$98.9K | 0.02% | 196 |
|
|
2014
Q2 | $253K | Hold |
800
| – | – | 0.01% | 210 |
|
|
2014
Q1 | $243K | Buy |
+800
| New | +$254K | 0.02% | 180 |
|
Other funds holding BIIB
Meag Munich Ergo's BIIB Position: Q1 2025 in Review
Meag Munich Ergo sold out of Biogen (BIIB) in Q1 2025, closing a stake of 518 shares — an estimated $77.8K sold.
Meag Munich Ergo first reported a position in BIIB in Q1 2014 and held it in 40 quarters. The position peaked at $14.7M in Q4 2015. 882 funds tracked by Wall St. Rank hold BIIB as of Q1 2025.
- Meag Munich Ergo reported no remaining Biogen position as of Q1 2025 after selling out during the quarter.
- Meag Munich Ergo sold 518 Biogen shares in Q1 2025, an estimated $77.8K.
- Meag Munich Ergo first reported a position in Biogen in Q1 2014 and held it in 40 quarters.
- Meag Munich Ergo's Biogen position peaked at $14.7M in Q4 2015.
- 882 funds tracked by Wall St. Rank held Biogen as of Q1 2025.
Based on Meag Munich Ergo's 13F filing for Q1 2025, filed 17 Apr 2025.